TP53 and CDKN2A Mutations Correlate with Survival, Stage, and Grade in Mesothelioma

被引：0
|
作者：
Zhu, Allen [1 ]
Husain, Aliya [1 ]
Hermina, Andrew [1 ]
Mueller, Jeffrey [2 ]
Kwon, Jung Woo [2 ]
机构：
[1] Univ Chicago, Chicago, IL USA
[2] Univ Chicago, Med Ctr, Chicago, IL USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1592
引用
收藏
页码：S1972 / S1973
页数：2
相关论文
共 50 条
  • [21] CDKN2A but not TP53 mutations nor HPV presence predict poor outcome in metastatic squamous cell carcinoma of the skin
    Kusters-Vandevelde, Heidi V. N.
    Van Leeuwen, Arjanne
    Verdijk, Marian A. J.
    de Koning, Maurits N. C.
    Quint, Wim G. V.
    Melchers, Willem J. G.
    Ligtenberg, Marjolijn J. L.
    Blokx, Willeke A. M.
    INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (09) : 2123 - 2132
  • [22] CDKN2A but not TP53 mutations nor HPV presence predict poor outcome in metastatic squamous cell carcinoma of the skin
    Kuesters-Vandevelde, V. H.
    Van Leeuwen, A.
    Verdijk, A. M.
    Koning, N. M.
    Quint, G. W.
    Melchers, J. W.
    Ligtenberg, J. M.
    Blokx, A. W.
    VIRCHOWS ARCHIV, 2009, 455 : 271 - 272
  • [23] BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma
    Christian Monnerat
    Agnès Chompret
    Caroline Kannengiesser
    Marie-Françoise Avril
    Nicolas Janin
    Alain Spatz
    Jean-Marc Guinebretière
    Catalin Marian
    Michel Barrois
    Françoise Boitier
    Gilbert M. Lenoir
    Brigitte Bressac-de Paillerets
    Familial Cancer, 2007, 6 : 453 - 461
  • [24] KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
    Cicenas, Jonas
    Kvederaviciute, Kotryna
    Meskinyte, Ingrida
    Meskinyte-Kausiliene, Edita
    Skeberdyte, Aiste
    Cicenas, Jonas, Jr.
    CANCERS, 2017, 9 (05):
  • [25] BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma
    Monnerat, Christian
    Chompret, Agnes
    Kannengiesser, Caroline
    Avril, Marie-Francois
    Janin, Nicolas
    Spatz, Alain
    Guinebretiere, Jean-Marc
    Marian, Catalin
    Barrois, Michel
    Boitier, Francois
    Lenoir, Gilbert M.
    Paillerets, Brigitte Bressac-de
    FAMILIAL CANCER, 2007, 6 (04) : 453 - 461
  • [26] Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues
    Voutsadakis, Ioannis A.
    Digklia, Antonia
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (01)
  • [27] Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy
    Malarikova, Diana
    Berkova, Adela
    Obr, Ales
    Blahovcova, Petra
    Svaton, Michael
    Forsterova, Kristina
    Kriegova, Eva
    Prihodova, Eva
    Pavlistova, Lenka
    Petrackova, Anna
    Zemanova, Zuzana
    Trneny, Marek
    Klener, Pavel
    CANCERS, 2020, 12 (08) : 1 - 13
  • [28] Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer
    Deneka, Alexander Y.
    Baca, Yasmine
    Serebriiskii, Ilya G.
    Nicolas, Emmanuelle
    Parker, Mitchell, I
    Nguyen, Theodore T.
    Xiu, Joanne
    Korn, W. Michael
    Demeure, Michael J.
    Wise-Draper, Trisha
    Sukari, Ammar
    Burtness, Barbara
    Golemis, Erica A.
    CLINICAL CANCER RESEARCH, 2022, 28 (09) : 1925 - 1937
  • [29] The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors
    Altman, Alon D.
    Nelson, Gregg S.
    Ghatage, Prafull
    McIntyre, John B.
    Capper, David
    Chu, Pamela
    Nation, Jill G.
    Karnezis, Anthony N.
    Han, Guangming
    Kalloger, Steve E.
    Koebel, Martin
    MODERN PATHOLOGY, 2013, 26 (09) : 1255 - 1263
  • [30] Targeting CDKN2A in Mesothelioma
    Fennell, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S18 - S19
12345